Constellation Energy
CEG
$270.74
+4.60%
Constellation Energy is the largest operator of carbon-free nuclear generation in the United States, producing electricity from nuclear, wind, solar, natural gas, and hydroelectric assets and selling power, capacity, and related energy products to utilities, municipalities, cooperatives, and commercial and residential customers across the Mid-Atlantic, Midwest, New York, ERCOT, and other deregulated power regions. Spun out of Exelon in 2022, the company occupies a distinctive position as a pure-play competitive power producer whose fleet of always-on nuclear baseload capacity is increasingly viewed as scarce strategic infrastructure rather than a commodity merchant asset. The investor narrative has pivoted decisively toward AI-driven electricity demand, with long-term nuclear power agreements with hyperscalers such as Alphabet and a reported 20-year Amazon deal, plus federal Department of Energy loan commitments to extend and restart plants, framing Constellation as a primary beneficiary of the data-center power buildout. That bullish structural story is being actively debated against a backdrop of a sharp multi-quarter share-price drawdown, elevated valuation multiples, and questions about whether contracted hyperscaler pricing can offset soft merchant power and capacity realizations.…
CEG
Constellation Energy
$270.74
Related headlines
Investment Opinion: Should I buy CEG Today?
Rating: Hold with a constructive bias toward accumulation on weakness. The core thesis is that Constellation's carbon-free nuclear fleet and hyperscaler contracts (Alphabet, a reported 20-year Amazon deal) make it a scarce AI-power infrastructure asset, but the current $271.37 price already discounts much of that story while reported free cash flow remains negative. The 22-analyst consensus of "buy" (mean 1.625) with an average target of $337.57 (+24.4% upside) anchors a favorable risk-reward skew, with the low target of $238.00 only 12.3% below spot versus a high target of $395.00 that is 45.6% above.
Supporting evidence is mixed but tilts positive on forward metrics: revenue grew +23.03% YoY to $7.506 billion in Q2 2026, the forward PE of 20.42x is a 57% compression from the 47.74x trailing multiple, ROE is a healthy 15.97%, and debt-to-equity of 0.62 is modest. However, the EV/EBITDA of 20.56x is roughly 70%-100% above the 10x-12x peer norm, PB of 7.62x is at the top of its historical band, free cash flow TTM of $309 million is thin against a $110.6 billion market cap, and Q2 operating margin compressed to 7.73%. The stock's -31.56% one-year decline and -47.09 relative strength versus the S&P 500 confirm the market has already begun discounting execution risk.
The biggest risks that could invalidate the thesis are (1) failure of hyperscaler contracts to convert into the $21.45 consensus EPS, (2) continued negative free cash flow forcing further balance-sheet leverage, and (3) valuation compression if Neutral-rated banks (Goldman, Citi, Mizuho) turn negative. This Hold would upgrade to Buy if the stock retests the $250-$255 shelf with stabilizing FCF, or if Q3/Q4 EPS tracks toward the $21.45 consensus; it would downgrade to Sell on a decisive break below $250 or if forward EPS guidance moves toward the $16.63 low. Net verdict: fairly valued on forward earnings, expensive on trailing and peer-relative metrics — a bet on execution rather than a statistical bargain.
Sign up to view all
CEG 12-Month Price Forecast
The forward-looking view is balanced: the AI-power contract narrative and 23% revenue growth provide a credible path to the $21.45 consensus EPS that would justify the 20.4x forward PE, and the asymmetric analyst target range ($238 low versus $395 high) favors patient accumulation near support. However, negative free cash flow in three of four quarters, a 70%-100% EV/EBITDA premium to peers, and a -31.56% one-year decline mean the market has already begun discounting execution risk, and the stock remains headline-driven around contract announcements. I would upgrade to bullish if Q3/Q4 results show EPS tracking toward $21.45 and free cash flow turning positive, or if the stock decisively breaks above $300-$315 on volume. I would downgrade to bearish on a break below the $250-$255 shelf or if forward EPS guidance moves toward the $16.63 low.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Constellation Energy's 12-month outlook, with a consensus price target around $338.21 and implied upside of +24.9% versus the current price.
Average Target
$338.21
0 analysts
Implied Upside
+24.9%
vs. current price
Analyst Count
—
covering this stock
Price Range
$238 - $395
Analyst target range
Coverage is deep and overwhelmingly constructive: 22 analysts cover Constellation with a consensus recommendation of "buy" (mean rating 1.625 on a 1-5 scale where 1 is Strong Buy), and the average target price of $337.57 implies +24.4% upside from the current $271.37. The consensus leans clearly bullish, with the average target sitting well above spot and the estimated EPS average of $21.45 versus a low of $16.63 and high of $26.64, a spread that reflects genuine uncertainty about how quickly the hyperscaler contracts ramp. Recent institutional actions support the bullish tilt — Morgan Stanley reiterated Overweight on September 18 and August 21, Argus reiterated Buy on August 11, and UBS, Barclays, TD Cowen, and Wells Fargo all reiterated Buy/Overweight in late July — though Goldman Sachs downgraded to Neutral from Buy on June 18 and Citigroup and Mizuho remain Neutral, suggesting the sell-side is bullish but not unanimous.\n\nThe target range of $238.00 to $395.00 is wide — a 66% spread from low to high — which signals high conviction dispersion rather than a tightly clustered consensus. The high target of $395 assumes successful execution of the AI-power contract pipeline, multiple expansion back toward the 52-week high of $406, and forward EPS toward the $26.64 high estimate; the low target of $238 sits just 12.3% below spot and roughly brackets the 52-week low of $228.63, implying that even the bear case does not price in a catastrophic outcome but rather margin compression and slower contract conversion. The fact that the low target is only modestly below the current price, while the high target is 45.6% above it, creates an asymmetric risk-reward skew that favors patient accumulation — provided the $250 support holds. The wide dispersion and the presence of Neutral ratings from major banks mean the stock is likely to remain headline-driven and volatile around contract announcements, so position sizing should account for the 1.13 beta and the -41.45% max drawdown rather than treating the consensus target as a near-term price objective.
Drowning in data?
Find the real signal!
Bulls vs Bears: CEG Investment Factors
The bull case rests on a genuine structural re-rating story — hyperscaler nuclear contracts, 23% revenue growth, and a forward PE of 20.4x that looks reasonable if the $21.45 EPS consensus is delivered — while the bear case rests on negative free cash flow, a 70%-100% EV/EBITDA premium to peers, and a stock that has lost 31.56% over the past year. On balance the evidence currently favors the bear side on reported fundamentals (three of four quarters with negative FCF, Q2 operating margin of 7.73%) but the bull side on forward-looking contract momentum and analyst conviction (22 analysts at a 1.625 mean rating, $337.57 average target). The single most important tension is whether contracted hyperscaler pricing can convert into the step-change earnings implied by the forward PE — if Q3/Q4 results show EPS tracking toward $21.45, the valuation is defensible; if not, the 47.74x trailing multiple and negative FCF become the dominant narrative.
Bullish
- Hyperscaler nuclear contracts validate demand: Constellation's long-term nuclear power agreements with Alphabet and a reported 20-year Amazon deal reframe the fleet as scarce AI infrastructure rather than commodity merchant capacity. The October 6 single-day +12.3% rally from $267.62 to $300.40 on the Alphabet headlines shows how quickly the market re-rates the stock on contract news. These agreements provide multi-decade revenue visibility that the merchant power book (which drove $4.959 billion of Q2 2026's $7.506 billion revenue) cannot.
- Revenue re-accelerating at 23% YoY: Q2 2026 revenue of $7.506 billion grew +23.03% versus $6.101 billion in Q2 2025, a clear re-acceleration from the prior-year base. Q1 2026 revenue of $11.122 billion further demonstrates the scale of the merchant-plus-contracted book. This growth trajectory is the fundamental engine behind the forward EPS consensus of $21.45.
- Asymmetric analyst risk-reward skew: The average target of $337.57 implies +24.4% upside from $271.37, while the low target of $238.00 sits only 12.3% below spot and roughly brackets the 52-week low of $228.63. With 22 analysts at a mean rating of 1.625 (buy) and a high target of $395.00 (+45.6%), the downside is bounded near the low target while the upside is nearly four times larger.
- Forward PE compression to 20.4x: The trailing PE of 47.74x compresses to a forward PE of 20.42x, a 57% de-rating that implies the market expects earnings to more than double toward the $21.45 consensus EPS. A 20.4x forward multiple is reasonable for a growth-inflected utility with contracted hyperscaler backlog, and the PS ratio of 4.33x sits in the lower-middle of its historical 3.4x-20.3x band.
Bearish
- Free cash flow deeply negative: Free cash flow TTM is only $309 million against a $110.6 billion market cap, and quarterly FCF was negative in three of the last four periods (-$118 million in Q2 2026, -$850 million in Q1 2026, -$181 million in Q4 2025). Capex of $1.246 billion in Q2 2026 alone, plus $1.971 billion of buybacks and $154 million of dividends, is being funded partly by debt repayment activity and investment maturities rather than organic cash generation.
- Steep premium to utility peers: The EV/EBITDA of 20.56x versus a sector norm closer to 10x-12x represents roughly a 70%-100% premium, and the PB of 7.62x is far above the sector's historical 1.5x-2.5x range. The PS of 4.33x and price-to-cash-flow of 26.1x mean the market is paying up for growth that has not yet materialized in reported results, leaving little room for execution disappointment.
- Margin volatility and Q2 compression: Q2 2026 operating margin compressed to 7.73% as operating expenses of $6.926 billion consumed nearly the entire revenue base, down sharply from Q1 2026's 20.84% operating margin and $1.603 billion net income. EBITDA margin has ranged from roughly 24% to 32% across recent quarters, and any compression toward the low end would challenge the premium valuation.
- Broken momentum and relative weakness: The stock is down -31.56% over one year and -25.91% YTD versus the S&P 500's +15.53% and +11.93%, producing a relative strength of -47.09 over twelve months. At $271.37 it sits at roughly 24.1% of its 52-week range and 33.2% below the $406.04 high, with a -41.45% max drawdown confirming a broken momentum name rather than an overextended one.
CEG Technical Analysis
Constellation is in a sustained, if volatile, downtrend on a trailing basis: the stock is down -31.56% over the past year and -25.91% year-to-date, a stark underperformance versus the S&P 500's +15.53% 1-year and +11.93% YTD returns, producing a relative strength of -47.09 over twelve months. At the current price of $271.37, the stock sits at roughly 24.1% of its 52-week range of $228.63 to $406.04, meaning it is trading in the lower quartile of its annual band and about 33.2% below the 52-week high. That positioning is characteristic of a broken momentum name rather than an overextended one — the stock has already absorbed a -41.45% max drawdown, so the risk is a falling knife rather than chasing a top, though the proximity to the 52-week low ($228.63, only 15.8% below spot) defines the downside boundary that must hold for the base-building thesis to survive.\n\nShort-term momentum has turned constructive and is diverging sharply from the longer-term trend: the stock is up +4.56% over one month and +7.52% over three months, outperforming SPY by +3.34 and +4.83 percentage points respectively, even as the six-month change remains -8.39% and the one-year change is deeply negative. This is a classic mean-reversion setup — the 1-month and 3-month trends are positive while the 1-year trend is negative, suggesting the selling pressure has exhausted and buyers are stepping in around the $250-$260 area, which was tested repeatedly in June and September. The most recent action reinforces the volatility: the stock spiked from $267.62 on October 5 to $300.40 on October 6 (a +12.3% single-day move, likely tied to the Alphabet nuclear agreement headlines) before fading back to $271.37 by October 16, a round-trip that signals event-driven trading rather than a clean trend. Volume of roughly 4.0 million shares and a short ratio of 4.04 days indicate moderate but not extreme positioning, leaving room for either a squeeze or further distribution.\n\nKey technical levels are well defined: support sits at the 52-week low of $228.63, with an intermediate shelf around $250-$255 where the stock bottomed in June and September, while resistance is anchored at the 52-week high of $406.04, with a nearer ceiling at the $300-$315 zone that rejected the October rally. A decisive breakout above $300 on volume would confirm the double-bottom/recovery thesis and open a path toward the $340s, whereas a breakdown below $250 would invalidate the base and put the $228.63 low in play, implying roughly 16% additional downside. The beta of 1.129 means the stock is about 13% more volatile than the market — meaningful but not extreme for a utility-adjacent name — which, combined with the -41.45% max drawdown, argues for smaller position sizing and wider stops than a typical defensive utility holding would warrant.
Beta
1.13
1.13x market volatility
Max Drawdown
-41.5%
Largest decline past year
52-Week Range
$229-$406
Price range past year
Annual Return
-24.5%
Cumulative gain past year
| Period | CEG Return | S&P 500 |
|---|---|---|
| 1m | +3.3% | -0.1% |
| 3m | -1.8% | +4.7% |
| 6m | -13.6% | +8.3% |
| 1y | -24.5% | +15.2% |
| ytd | -26.1% | +13.4% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
CEG Fundamental Analysis
Revenue is growing at a robust clip and re-accelerating: Q2 2026 revenue of $7.506 billion rose +23.03% year-over-year versus $6.101 billion in Q2 2025, and the sequential trajectory has been strong, with Q1 2026 revenue of $11.122 billion and Q4 2025 of $5.46 billion. The segment mix shows power and power-related revenues of $4.959 billion dominating the top line, supplemented by $2.149 billion of other revenues and $396 million of capacity revenues, meaning the merchant power book — not contracted capacity — is the primary swing factor. The growth trend supports the AI-power investment case, but the lumpiness (Q1 revenue more than double Q4) reflects seasonal and mark-to-market dynamics in a merchant model, so investors should focus on contracted nuclear agreements as the durable growth driver rather than extrapolating quarterly revenue spikes.\n\nProfitability is positive but uneven: Q2 2026 net income was $513 million (a 6.83% net margin) on $1.88 billion of EBITDA (25.05% EBITDA margin), down from Q1 2026's $1.603 billion net income and $3.534 billion EBITDA, which had benefited from a 20.84% operating margin. The trailing net margin of 9.08% and operating margin of 12.09% are respectable for an independent power producer but well below the 18.4% gross margin reported at the consolidated level, and the Q2 operating margin compressed to 7.73% as operating expenses of $6.926 billion consumed nearly the entire revenue base. The key watch item is margin durability: Q1's 42.9% gross margin versus Q2's reported 100% gross margin (a presentation artifact from cost classification) makes clean comparison difficult, but the underlying EBITDA margin has ranged from roughly 24% to 32% across recent quarters, and any compression toward the low end would challenge the premium valuation.\n\nThe balance sheet is serviceable but cash generation is the weak link: debt-to-equity is 0.62, the current ratio is 1.53, and ROE is a healthy 15.97%, but free cash flow TTM is only $309 million against a $110.6 billion market cap, and quarterly FCF has been negative in three of the last four periods (-$118 million in Q2 2026, -$850 million in Q1 2026, -$181 million in Q4 2025). Capital expenditures are heavy — $1.246 billion in Q2 2026 alone — and the company returned capital via $1.971 billion of buybacks and $154 million of dividends in Q2, funded partly by $2.262 billion of debt repayment activity and investment maturities, which explains the thin FCF. With a dividend yield of just 0.44% and a payout ratio of 20.96%, the dividend is not the story; the question is whether operating cash flow of $1.128 billion in Q2 can scale fast enough to cover the capex and buyback program without further balance-sheet leverage.
Quarterly Revenue
$7.5B
2026-06
Revenue YoY Growth
+23.0%
YoY Comparison
Gross Margin
100.0%
Latest Quarter
Free Cash Flow
$309000000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is CEG Overvalued?
Because net income is positive ($513 million in Q2 2026), the PE ratio is the appropriate primary metric, and it tells a bifurcated story: the trailing PE is 47.74x while the forward PE is 20.42x, a 57% compression that implies the market expects earnings to more than double. That gap is the crux of the valuation debate — the forward multiple of 20.4x is reasonable for a growth-inflected utility, but it depends entirely on delivering the consensus EPS of $21.45 versus the trailing EPS of $0.02, a forecast that requires the contracted nuclear agreements to translate into step-change earnings.\n\nRelative to the Utilities sector, Constellation trades at a steep premium: its PS ratio of 4.33x and EV/EBITDA of 20.56x are well above typical regulated utility multiples in the low-to-mid teens, and its PB of 7.62x is far above the sector's historical 1.5x-2.5x range. The premium is partially justified by the company's unique carbon-free nuclear fleet and hyperscaler contract backlog, but the PEG ratio of -1.26 (negative due to the near-zero trailing EPS base) and the 26.1x price-to-cash-flow ratio suggest the market is paying up for growth that has not yet fully materialized in reported results. Against independent power producer peers, the EV/EBITDA of 20.6x versus a sector norm closer to 10x-12x represents roughly a 70%-100% premium, which is defensible only if contracted AI-power revenue commands structurally higher margins.\n\nHistorically, the stock's own valuation band has been wide: the PE ratio ranged from 15.5x in Q1 2026 to 132.7x in Q1 2025, and the PS ratio ranged from 3.4x in Q1 2023 to 20.3x in Q4 2025, with the current 4.33x PS sitting in the lower-middle of that range. The PB ratio of 7.62x, however, is near the top of its historical band (which has ranged from roughly 1.2x in 2021 to 7.6x now), reflecting both accumulated equity growth and the market's willingness to pay a premium for the nuclear asset base. Net-net, the stock is expensive on trailing metrics but not extreme on forward earnings or PS relative to its own history — the valuation is a bet on execution of the contracted-growth story rather than a statistical bargain.
PE
47.7x
Latest Quarter
vs. Historical
Low-End
5-Year PE Range 6x~133x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
20.6x
Enterprise Value Multiple
Investment Risk Disclosure
Financial and operational risks center on cash generation and margin durability. Free cash flow TTM of just $309 million against a $110.6 billion market cap is thin, with negative FCF in three of the last four quarters (-$118 million in Q2 2026, -$850 million in Q1 2026, -$181 million in Q4 2025) as capex of $1.246 billion in Q2 alone plus $1.971 billion of buybacks outran operating cash flow of $1.128 billion. Revenue concentration in the merchant power book ($4.959 billion of Q2's $7.506 billion) means mark-to-market and seasonal swings drive results, evidenced by Q1 revenue of $11.122 billion versus Q4 2025's $5.46 billion. Margin volatility is real: Q2 2026 operating margin fell to 7.73% from Q1's 20.84%, and EBITDA margin has ranged from roughly 24% to 32%, so any drift toward the low end would undermine the premium multiple. Debt-to-equity of 0.62 and a current ratio of 1.53 are serviceable but leave limited cushion if merchant realizations soften while capex stays elevated.
Market and competitive risks are dominated by valuation compression. The EV/EBITDA of 20.56x versus a 10x-12x peer norm and PB of 7.62x versus a 1.5x-2.5x sector range mean the stock carries a 70%-100% premium that requires flawless execution of the hyperscaler contract pipeline. The beta of 1.129 means roughly 13% more volatility than the market, and the -41.45% max drawdown shows how violently the stock de-rates when the AI-power narrative wobbles. Recent news highlights emerging competitive threats: Motley Fool argued Cameco offers better risk-reward given Constellation's stretched valuation, and Talen Energy's 12.4% jump on the same Google-Constellation headlines shows capital rotating to cheaper nuclear peers. Sell-side conviction is not unanimous — Goldman Sachs downgraded to Neutral on June 18 and Citigroup and Mizuho remain Neutral — so negative headlines around contract pricing or merchant power realizations could trigger further downgrades.
The worst-case scenario is a chain in which hyperscaler contract announcements fail to convert into reported EPS, merchant power and capacity realizations stay soft, and Q3/Q4 earnings come in toward the $16.63 low estimate rather than the $21.45 consensus. That would leave the forward PE well above 20x on realized numbers, prompt the Neutral-rated banks to turn negative, and push the stock toward the analyst low target of $238.00 (12.3% below spot) and then the 52-week low of $228.63 (15.8% below spot). A break below the $250-$255 shelf that held in June and September would invalidate the base-building thesis and put the $228.63 low in play, implying roughly -16% from the current $271.37; a deeper drawdown toward the -41.45% historical max would imply a price near $159, though the bounded analyst low target makes that tail scenario less likely than a test of the 52-week low.
FAQ
Ranked by severity: first, financial risk — free cash flow TTM of only $309 million with negative FCF in three of the last four quarters (-$118 million in Q2 2026, -$850 million in Q1 2026) while capex runs at $1.246 billion per quarter. Second, valuation risk — EV/EBITDA of 20.56x versus a 10x-12x peer norm and PB of 7.62x at the top of its historical band leave little room for execution disappointment. Third, company-specific execution risk — the forward PE of 20.42x depends on delivering $21.45 EPS versus a $16.63 low estimate, a wide $10 spread that reflects genuine uncertainty about contract ramp timing. Fourth, macro and competitive risk — the 1.129 beta and -41.45% max drawdown show high sensitivity to narrative shifts, and capital is rotating to cheaper nuclear peers like Cameco and Talen Energy on the same headlines.
The 12-month forecast has three scenarios: a base case (50% probability) targeting $271-$338 as EPS lands near the $21.45 consensus and the $250-$255 shelf holds; a bull case (25% probability) targeting $337-$395 if hyperscaler contracts convert into earnings toward the $26.64 high estimate and the stock breaks above $300-$315 resistance; and a bear case (25% probability) targeting $228-$250 if EPS drifts toward the $16.63 low and the stock tests the analyst low target of $238.00 and the 52-week low of $228.63. The base case is most likely, with the key assumption being delivery of roughly $21.45 forward EPS that validates the 20.4x forward multiple. The wide $238-$395 analyst target range (a 66% spread) signals high conviction dispersion, so expect headline-driven volatility around contract announcements.
The valuation is bifurcated: the trailing PE of 47.74x and PB of 7.62x (near the top of its historical 1.2x-7.6x band) look expensive, but the forward PE of 20.42x is a 57% compression that implies earnings more than double to the $21.45 consensus. Relative to peers, the EV/EBITDA of 20.56x is roughly 70%-100% above the 10x-12x independent power producer norm, while the PS of 4.33x sits in the lower-middle of its own 3.4x-20.3x historical range. The market is paying a clear premium for the carbon-free nuclear fleet and hyperscaler contract backlog, implying it expects contracted AI-power revenue to command structurally higher margins. Net-net, the stock is fairly valued on forward earnings and expensive on trailing and peer-relative metrics — a bet on execution rather than a statistical bargain.
From a risk/reward perspective, CEG offers an asymmetric setup: the analyst average target of $337.57 implies +24.4% upside while the low target of $238.00 is only 12.3% below the current $271.37, and the high target of $395.00 is 45.6% above. The 22-analyst consensus of "buy" (mean 1.625) supports the constructive view, and the forward PE of 20.42x is reasonable if the $21.45 EPS consensus is delivered. The biggest downside risk is that hyperscaler contracts fail to convert into reported earnings, leaving the 47.74x trailing PE and negative free cash flow exposed. It is a good buy for patient investors with a 12-24 month horizon who can tolerate the 1.129 beta and -41.45% max drawdown, particularly on retests of the $250-$255 support shelf; it is less suitable for income or low-volatility investors given the 0.44% dividend yield.
CEG is better suited to a medium-to-long-term holding period of 12-24 months than to short-term trading, given the multi-decade hyperscaler contract structure (Alphabet agreements and a reported 20-year Amazon deal) that drives the thesis and the lumpy quarterly earnings that make near-term price action headline-driven. The beta of 1.129 and -41.45% max drawdown mean short-term traders face violent swings — the stock moved +12.3% in a single day on October 6 before fading back — while the 0.44% dividend yield and 20.96% payout ratio offer no income cushion for patient holders. Earnings visibility is improving as contracted revenue ramps, but the negative free cash flow in three of four quarters means the long-term case depends on capex normalizing. A concrete suggested minimum holding period is 12 months, ideally entered near the $250-$255 support shelf with position sizing that accounts for the 1.129 beta.
